What is claimed is:

1. A salt, which is 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid) di-hydrochloric acid salt.

2. The salt of claim 1, having Form I, wherein Form I has at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 8.5, 9.6, 9.9, 11.8, 12.3, 13.1, 13.4, 13.8, 14.2, 14.5, 15.4, 15.8, 16.8, 17.3 and 17.6 degrees.

3. The salt of claim 2, having an X-ray powder diffraction pattern as substantially shown in Figure 7.

4. The salt of claim 2, having a first endothermic peak with an onset temperature at 31.1 ± 3 ºC and a maximum at 91.4 ± 3 ºC, and a second endothermic peak with an onset temperature at 231.0 ± 3 ºC and a maximum at 236.4 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

5. The salt of claim 1, having Form II, wherein Form II has at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 4.6, 6.9, 8.9, 11.2, 11.7, 13.2, 13.9, 14.3, 14.8, 16.0, 16.7, 17.2, 17.9, 25.3 and 25.6 degrees.

6. The salt of claim 5, having an X-ray powder diffraction pattern as substantially shown in Figure 11.

7. The salt of claim 5, having a first endothermic peak with an onset temperature at 22.2 ºC and a maximum at 89.7 ºC, and a second endothermic peak with an onset temperature at 251.7 ºC and a maximum at 258.3 ºC in a differential scanning calorimetry (DSC) thermogram.

8. The salt of claim 1, having Form III, wherein Form III has at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 9.2, 11.2, 14.9, 17.0, 17.8, 19.7, 24.4 and 25.9 degrees.

9. The salt of claim 8, having an X-ray powder diffraction pattern as substantially shown in Figure 14.

10. The salt of claim 8, having an endothermic peak with an onset temperature of 247 ± 3 ºC and a maximum at 258 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

11. The salt of claim 1, having Form IV, wherein Form IV has at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.4, 8.8, 10.9, 13.0, 15.1, 16.2, 17.5, 21.9 and 26.3 degrees.

12. The salt of claim 11, having an X-ray powder diffraction pattern as substantially shown in Figure 17.

13. The salt of claim 11, having an endothermic peak with an onset temperature of 268 ± 3 ºC and a maximum at 273 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

14. The salt of claim 1, having Form V, wherein Form V has at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.8, 9.1, 13.4, 14.8, 16.6, 17.1, 18.1 and 19.3 degrees.

15. The salt of claim 14, having an X-ray powder diffraction pattern as substantially shown in Figure 21.

16. The salt of claim 14, having an endothermic peak with an onset temperature of 241 ± 3 ºC and a maximum at 249 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

17. The salt of claim 1, having Form VII, wherein Form VII has at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 9.9, 11.5, 14.1, 14.9, 17.0 and 24.4 degrees.

18. The salt of claim 17, having an X-ray powder diffraction pattern as substantially shown in Figure 29.

19. The salt of claim 17, having a first endothermic peak with an onset temperature at 44 ± 3 ºC and a maximum at 85 ± 3 ºC, and a second endothermic peak with an onset temperature at 260 ± 3 ºC and a maximum at 274 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

20. The salt of claim 1, having Form VIII, wherein Form VIII has at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.6, 11.2, 13.1, 14.7, 16.7, 19.0 and 24.1 degrees.

21. The salt of claim 20, having an X-ray powder diffraction pattern as substantially shown in Figure 33.

22. The salt of claim 20, having a first endothermic peak with an onset temperature at 44 ± 3 ºC and a maximum at 78 ± 3 ºC, and a second endothermic peak with an onset

temperature at 246 ± 3 ºC and a maximum at 253 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

23. The salt of claim 1, having Form IX, wherein Form IX has at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 3.8, 6.6, 10.7, 13.1, 15.3, 16.3, 17.5 and 19.1 degrees.

24. The salt of claim 23, having an X-ray powder diffraction pattern as substantially shown in Figure 37.

25. The salt of claim 23, having a first endothermic peak with an onset temperature at 43 ± 3 ºC and a maximum at 64 ± 3 ºC, and a second endothermic peak at 116 ± 3 ºC and a maximum at 132 ± 3 ºC, and a third endothermic peak at 266 ± 3 ºC and a maximum at 276 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

26. A salt, which is 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid) mono-hydrochloric acid salt.

27. The salt of claim 26, having Form VI, wherein Form VI has at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.4, 11.1, 12.6, 13.8, 14.6, 15.7, 16.9, 17.6, 19.0 and 19.5 degrees.

28. The salt of claim 27, having an X-ray powder diffraction pattern as substantially shown in Figure 25.

29. The salt of claim 27, having a first endothermic peak with an onset temperature at 44 ± 3 ºC and a maximum at 77 ± 3 ºC, and a second endothermic peak with an onset temperature at 244 ± 3 ºC and a maximum at 251 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

30. A salt, which is 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid) di-sodium salt.

31. The salt of claim 30, having an X-ray powder diffraction pattern as substantially shown in Figure 4.

32. The salt of claim 30, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.3, 7.1, 10.6, 13.9, 14.3, 16.1 and 17.4 degrees.

33. The salt of claim 30, having a first endothermic peak with an onset temperature of 47 ± 3 ºC and a maximum at 108 ± 3 ºC and a second endothermic peak with an onset temperature of 258 ± 3 ºC and a maximum at 280 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

34. A pharmaceutical composition comprising a salt of any one of claims 1-33 and a pharmaceutically acceptable carrier or excipient.

35. A solid oral dosage form comprising the pharmaceutical composition of claim 34.

36. A method of inhibiting PD-1/PD-L1 interaction, said method comprising contacting tumor cells *in vitro* with a salt of any one of claims 1-33.

37. Use of a salt of any one of claims 1-33 in the manufacture of a medicament for the treatment of a disease or disorder associated with inhibition of PD-1/PD-L1 interaction, wherein the disease or disorder is cancer or an infection.

38. The use according to claim 37, wherein the disease or disorder is cancer, and the cancer is a metastatic cancer that expresses PD-L1, lung cancer, non-small cell lung cancer, hepatic cancer, melanoma, cancer of the bladder, cancer of the urethra, renal cancer, or clear cell carcinoma.

39. Use of a salt of any one of claims 1-33 in the manufacture of a medicament to enhance, stimulate, and/or increase the immune response in a patient to cancer.

40. A process of preparing the salt of claim 1, comprising reacting said Compound 1 with at least two equivalents of hydrochloric acid.

41. A process of preparing the salt of any one of claims 2-4, comprising:

a) preparing a suspension of Compound 1 and at least 2 equivalents of hydrochloric acid in a solvent comprising acetone;

b) heating the suspension of a) to above room temperature to form a clear solution;

c) cooling the clear solution of b) to about room temperature;

d) adding a solvent comprising acetone to the mixture of c) to form a cloudy solution; and

e) filtering the cloudy solution of d) to provide said Form I as a solid.